Middle East And Africa Liver Cancer Diagnostics Market
حجم السوق بالمليار دولار أمريكي
CAGR :
% 
 فترة التنبؤ |
2023 –2030 |
 حجم السوق (السنة الأساسية) |
USD 263.95 Million |
 حجم السوق (سنة التنبؤ) |
USD 365.62 Million |
 CAGR |
% |
| Major Markets Players |
سوق تشخيص سرطان الكبد في الشرق الأوسط وأفريقيا، حسب نوع الاختبار (اختبار التصوير، الخزعة، الاختبار الجينومي ، وغيرها)، مراحل السرطان (المرحلة 0، المرحلة الأولى، المرحلة الثانية، المرحلة الثالثة، والمرحلة الرابعة)، نوع السرطان (سرطان الكبد الأولي وسرطان الكبد الثانوي)، المنتج (المنتجات القائمة على المنصة، المنتجات القائمة على الأدوات، الأدوات والكواشف، والمواد الاستهلاكية الأخرى)، التكنولوجيا (التهجين الموضعي الفلوري، التسلسل الجيني للجيل التالي، المقايسة المناعية الفلورية، التهجين الجينومي المقارن، المناعة الكيميائية، وغيرها)، التطبيق (الفحص والتشخيص والتنبؤ والتنبؤ والبحث)، الجنس (أنثى وذكور)، المستخدم النهائي (المستشفيات ومراكز التشخيص ومراكز أبحاث السرطان والمعاهد الأكاديمية ومراكز الجراحة الخارجية وغيرها)، قناة التوزيع (العطاء المباشر ومبيعات التجزئة وغيرها) - اتجاهات الصناعة والتوقعات حتى عام 2030.
تحليل ورؤى حول سوق تشخيص سرطان الكبد في الشرق الأوسط وأفريقيا
من المتوقع أن ينمو سوق تشخيص سرطان الكبد في الشرق الأوسط وأفريقيا في العام المتوقع بسبب زيادة عدد اللاعبين في السوق وتوافر الخدمات المتقدمة. إلى جانب ذلك، يشارك المصنعون في أنشطة البحث والتطوير لإطلاق خدمات جديدة في السوق. ومن المتوقع أن يعزز الطلب المتزايد على رعاية صحية ذات جودة أفضل لسرطان الكبد والتفضيل المتزايد للفحوصات الصحية الوقائية نمو السوق.
ومع ذلك، من المتوقع أن تشكل التكلفة العالية لإجراءات التشخيص ونقص المتخصصين المهرة والمعتمدين تحديًا لنمو السوق.
من المتوقع أن يحقق سوق تشخيص سرطان الكبد في الشرق الأوسط وأفريقيا نموًا في السوق في الفترة المتوقعة من 2023 إلى 2030. تحلل شركة Data Bridge Market Research أن السوق ينمو بمعدل نمو سنوي مركب قدره 4.2٪ في الفترة المتوقعة من 2023 إلى 2030 ومن المتوقع أن يصل إلى 365.62 مليون دولار أمريكي بحلول عام 2030 من 263.95 مليون دولار أمريكي في عام 2022.
سيساعدك فريقنا في إنشاء حل مؤثر على الإيرادات لتحقيق هدفك المنشود. إن قابلية التوسع وتوسع أعمال وحدات البيع بالتجزئة في البلدان النامية في مختلف المناطق والشراكة مع الموردين للتوزيع الآمن للآلات ومنتجات الأدوية هي المحركات الرئيسية التي دفعت الطلب في السوق خلال فترة التنبؤ.
|
تقرير القياس |
تفاصيل |
|
فترة التنبؤ |
2023 إلى 2030 |
|
سنة الأساس |
2022 |
|
سنوات تاريخية |
2021 (قابلة للتخصيص حتى 2015-2020) |
|
وحدات كمية |
الإيرادات بالملايين من الدولارات الأمريكية |
|
القطاعات المغطاة |
By Test Type (Imaging Test, Biopsy, Genomic Test, and Others), Cancer Stages (Stage 0, Stage I , Stage II, Stage III, and Stage IV), Cancer Type (Primary Liver Cancer and Secondary Liver Cancer), Product (Platform-Based Products, Instrument Based Products, Kits and Reagents, and Other Consumables), Technology (Fluorescent In Situ Hybridization, Next Generation Sequencing, Fluorimmunoassay, Comparative Genomic Hybridization, Immunohistochemical, and Others), Application (Screening, Diagnostic and Predictive, Prognostic, and Research), Gender (Female and Male), End-User (Hospitals, Diagnostic Centers, Cancer Research Centers, Academic Institutes, Ambulatory Surgical Centers, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others) |
|
Countries Covered |
South Africa, Saudi Arabia, Egypt, Israel and the Rest of Middle East and Africa |
|
Market Players Covered |
Siemens Healthcare GmbH (Germany), Koninklijke Philips N.V.(Netherland), Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), QIAGEN(U.S.), F. Hoffmann-La Roche Ltd(Switzerland), FUJIFILM Corporation (Japan), BD(U.S.), and Sysmex Corporation (Japan) among others. |
Market Definition
Liver cancer diagnostics refers to the various methods and techniques used to detect and diagnose liver cancer. This may include laboratory tests, imaging tests, and physical examinations.
The liver cancer diagnostic market includes a wide range of products and services from various companies, including diagnostic laboratories, medical device manufacturers, and pharmaceutical companies. The market is driven by the increasing incidence of liver cancer and the growing demand for accurate and reliable diagnostic tests.
Middle East and Africa Liver Cancer Diagnostics Market Dynamics
Drivers
-
Unmet need for non-invasive, accurate, and reliable diagnostic tests for earlier cancer detection
Diagnostics is also becoming an increasingly important tool for converting the most recent developments in basic research into better clinical outcomes for patients. The development of novel, quick, sensitive, less invasive, and more accurate molecular diagnostic tests is being accelerated by some of the most exciting scientific developments of the time, including genomics, proteomics, and other "omics" technologies. This significantly impacts the ability to identify and treat different cancers earlier and more precisely. By customizing medicines based on each patient's distinct molecular profile, diagnostics help doctors make better-educated treatment decisions.
Thus, the unmet need for non-invasive, accurate, and reliable diagnostic tests for earlier cancer detection demands is expected to drive the market's growth.
-
Increasing early diagnosis of liver cancer
Machine learning could revolutionize early cancer diagnosis, which trains computers to see patterns in complex data. Tools include assessments of common health data, medical imaging, biopsy samples, and blood tests to help in early diagnosis and risk stratification. In many tumor types, the likelihood of undergoing successful therapy increases with an early cancer diagnosis. One important strategy is to assess patients at risk who do not exhibit symptoms and respond quickly and appropriately to those who do.
Thus, earlier detection improves treatment options, patient outcomes, and survival and is expected to drive the growth of the Middle East & Africa liver cancer diagnostics market.
Restraint
-
Barriers to liver cancer diagnosis and poor prognosis
Cancer is the leading cause of death in developed and developing countries. Cancer mortality is expected to rise to an estimated 13.1 million deaths annually by 2030. However, certain types of cancer have a high chance of being cured if they are detected at an early stage and adequately treated. The delays in cancer diagnosis may occur throughout the diagnostic pathway: patient, primary care, and secondary care. Patient delays may occur when the patient fails to recognize and act on suspicious cancer symptoms. Poor public awareness of early cancer symptoms is considered the predominant reason for delayed presentation, particularly if symptoms are atypical in nature.
The late diagnosis often results from these factors, which result in poor prognosis. Thus, these are expected to restrain the growth of the Middle East & Africa liver cancer diagnostics market.
Opportunity
-
Increasing awareness towards liver cancer
Liver cancer awareness is a chance to increase knowledge about these diseases and to put the spotlight on research into their causes, prevention, diagnosis, treatment, and survival. The objective is to assist persons who have been impacted by the liver and to promote healthy habits. Primary liver cancer is the name for cancer that develops in the liver. Hepatocellular carcinoma is the most prevalent type of primary liver cancer in adults (HCC). The third most common cause of cancer-related fatalities worldwide is this particular form of liver cancer. About 25,000 men and 11,000 women are diagnosed with liver cancer each year in the US, and the illness claims the lives of 19,000 men and 9,000 women.
Thus, government initiatives toward liver cancer diagnostics is expected to create an opportunity for the growth of the market.
Challenge
- Strict regulations for the approval of liver cancer diagnostic products
The strict guidelines for product approval and market commercialization are proving to be a major obstacle for manufacturers of cancer diagnostic products worldwide. Every nation has its own regulations and employs a different regulating body.
يتعين على اللاعبين المشاركين في إنتاج وتسويق الأجهزة الطبية التكيف نتيجة للقواعد الصارمة. وهذا من شأنه أن يؤثر على جميع أصحاب المصلحة على مستوى العالم، ومن المتوقع أن يشكل تحديًا للسوق طوال فترة التوقعات. وبالتالي، من المتوقع أن يشكل تحديًا لسوق تشخيص سرطان الكبد في الشرق الأوسط وأفريقيا مما يعيق نموها.
التطورات الأخيرة
- في ديسمبر 2022، أعلنت شركة FUJIFILM Holdings America Corporation أن الشركة لديها أصول اتفاقية شراء مع Inspirata، Inc. للاستحواذ على أعمال علم الأمراض الرقمية لتوسيع عرض التصوير المؤسسي القوي. يؤدي هذا إلى تمكين دمج صور وبيانات علم الأمراض في نظام السجلات الصحية الإلكترونية لمؤسسة الرعاية الصحية لتبسيط تقديم الرعاية لمرضى الأورام
نطاق سوق تشخيص سرطان الكبد في الشرق الأوسط وأفريقيا
يتم تصنيف سوق تشخيص سرطان الكبد في الشرق الأوسط وأفريقيا إلى تسعة قطاعات بارزة، وهي نوع الاختبار، ونوع السرطان، ومراحل السرطان، والمنتج، والتطبيق، والتكنولوجيا، والجنس، والمستخدم النهائي، وقنوات التوزيع.
حسب نوع الاختبار
- اختبار التصوير
- الخزعة
- اختبار الجينوم
- آحرون
حسب مراحل السرطان
- المرحلة 0
- المرحلة الأولى
- المرحلة الثانية
- المرحلة الثالثة
- المرحلة الرابعة
حسب نوع السرطان
- سرطان الكبد الأولي
- سرطان الكبد الثانوي
حسب المنتج
- المنتجات القائمة على المنصة
- المنتجات القائمة على الآلات
- أطقم ومواد كيميائية
- المواد الاستهلاكية الأخرى
حسب التكنولوجيا
- التهجين الفلوري في الموقع
- تسلسل الجيل القادم
- اختبار المناعة الفلوري
- التهجين الجينومي المقارن
- مناعة نسيجية كيميائية
- آحرون
حسب الطلب
- الفحص
- التشخيص والتنبؤ
- التنبؤ
- بحث
حسب الجنس
- أنثى
- ذكر
حسب المستخدم النهائي
- المستشفيات
- مراكز أبحاث السرطان
- المعاهد الأكاديمية
- مراكز التشخيص
- مراكز الجراحة الخارجية
- آحرون
حسب قناة التوزيع
- العطاءات المباشرة
- مبيعات التجزئة
- آحرون
تحليل/رؤى إقليمية لسوق تشخيص سرطان الكبد في الشرق الأوسط وأفريقيا
يتم تقسيم سوق تشخيص سرطان الكبد في الشرق الأوسط وأفريقيا إلى تسعة قطاعات بارزة بناءً على نوع الاختبار ومراحل السرطان ونوع السرطان والمنتج والتطبيق والتكنولوجيا والجنس والمستخدم النهائي وقناة التوزيع.
الدول التي يغطيها تقرير السوق هذا هي جنوب أفريقيا والمملكة العربية السعودية والإمارات العربية المتحدة ومصر وإسرائيل وبقية دول الشرق الأوسط وأفريقيا.
وتتصدر المملكة العربية السعودية هذا المجال بفضل التقدم التكنولوجي الكبير في منتجات التشخيص.
كما يوفر قسم الدولة في التقرير عوامل التأثير الفردية على السوق والتغييرات في التنظيم في السوق محليًا والتي تؤثر على الاتجاهات الحالية والمستقبلية للسوق. تعد نقاط البيانات مثل المبيعات الجديدة ومبيعات الاستبدال والتركيبة السكانية للدولة والقوانين التنظيمية ورسوم الاستيراد والتصدير من بين المؤشرات الرئيسية المستخدمة للتنبؤ بسيناريو السوق للدول الفردية. كما يتم النظر في وجود وتوافر العلامات التجارية في الشرق الأوسط وأفريقيا والتحديات التي تواجهها بسبب المنافسة الكبيرة أو النادرة من العلامات التجارية المحلية والمحلية وتأثير قنوات المبيعات أثناء تقديم تحليل تنبؤي لبيانات الدولة.
تحليل المنافسة وحصة سوق تشخيص سرطان الكبد في الشرق الأوسط وأفريقيا
يقدم المشهد التنافسي لسوق تشخيص سرطان الكبد في الشرق الأوسط وأفريقيا تفاصيل حسب المنافس. تتضمن التفاصيل نظرة عامة على الشركة، والبيانات المالية للشركة، والإيرادات المتولدة، وإمكانات السوق، والاستثمار في البحث والتطوير، ومبادرات السوق الجديدة، ومواقع الإنتاج والمرافق، ونقاط القوة والضعف في الشركة، وإطلاق المنتج، وموافقات المنتج، وعرض المنتج ونفسه، وهيمنة التطبيق، ومنحنى شريان الحياة التكنولوجي. ترتبط نقاط البيانات المذكورة أعلاه فقط بتركيز الشركة على سوق تشخيص سرطان الكبد في الشرق الأوسط وأفريقيا.
بعض اللاعبين الرئيسيين العاملين في سوق تشخيص سرطان الكبد في الشرق الأوسط وأفريقيا هم Siemens Healthcare GmbH (ألمانيا)، Koninklijke Philips NV (هولندا)، Illumina، Inc. (الولايات المتحدة)، Thermo Fisher Scientific Inc. (الولايات المتحدة)، QIAGEN (الولايات المتحدة)، F. Hoffmann-La Roche Ltd (سويسرا)، FUJIFILM Corporation (اليابان)، BD (الولايات المتحدة)، Sysmex Corporation (اليابان)، من بين آخرين.
SKU-
احصل على إمكانية الوصول عبر الإنترنت إلى التقرير الخاص بأول سحابة استخبارات سوقية في العالم
- لوحة معلومات تحليل البيانات التفاعلية
- لوحة معلومات تحليل الشركة للفرص ذات إمكانات النمو العالية
- إمكانية وصول محلل الأبحاث للتخصيص والاستعلامات
- تحليل المنافسين باستخدام لوحة معلومات تفاعلية
- آخر الأخبار والتحديثات وتحليل الاتجاهات
- استغل قوة تحليل المعايير لتتبع المنافسين بشكل شامل
Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET APPLICATION COVERAGE GRID
2.8 TEST TYPE LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTLE ANALYSIS
4.2 PORTER ANALYSIS
4.3 EPIDEMIOLOGY
5 MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET, REGULATIONS
6 INDUSTRY INSIGHTS
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 UNMET NEED FOR NON-INVASIVE, ACCURATE, AND RELIABLE DIAGNOSTIC TESTS FOR EARLIER CANCER DETECTION
7.1.2 INCREASING EARLY DIAGNOSIS OF LIVER CANCER
7.1.3 INCREASING CASES OF LIVER CANCER
7.1.4 RISE IN DIAGNOSTIC PRODUCT APPROVALS
7.2 RESTRAINTS
7.2.1 BARRIERS TO LIVER CANCER DIAGNOSIS AND POOR PROGNOSIS
7.2.2 HIGH FALSE-POSITIVES AND POOR SENSITIVITY OF LIVER CANCER DIAGNOSIS
7.3 OPPORTUNITIES
7.3.1 INCREASING AWARENESS TOWARDS LIVER CANCER
7.3.2 GOVERNMENT INITIATIVES TOWARD LIVER CANCER DIAGNOSTICS
7.3.3 GROWING DEMAND FOR BETTER QUALITY HEALTHCARE
7.4 CHALLENGES
7.4.1 STRICT REGULATIONS FOR THE APPROVAL OF LIVER CANCER DIAGNOSTIC PRODUCTS
7.4.2 LACK OF SKILLED AND CERTIFIED EXPERTISE
8 MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE
8.1 OVERVIEW
8.2 IMAGING TEST
8.2.1 MAGNETIC RESONANCE IMAGING (MRI)
8.2.1.1 MR ANGIOGRAPHY (MRA)
8.2.1.2 MR CHOLANGIOPANCREATOGRAPHY
8.2.2 COMPUTED TOMOGRAPHY
8.2.3 POSITRON EMISSION TOMOGRAPHY
8.2.4 ULTRASOUND
8.2.5 OTHERS
8.3 GENOMIC TEST
8.4 BIOPSY
8.4.1 FINE NEEDLE ASPIRATION BIOPSY
8.4.2 CORE NEEDLE BIOPSY
8.4.3 LAPAROSCOPY
8.5 OTHERS
9 MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET, BY CANCER STAGE
9.1 OVERVIEW
9.2 STAGE III
9.3 STAGE II
9.4 STAGE IV
9.5 STAGE I
9.6 STAGE 0
10 MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE
10.1 OVERVIEW
10.2 SECONDARY LIVER CANCER
10.2.1 HEMANGIOMA
10.2.2 HEPATIC ADENOMA
10.2.3 FOCAL NODULAR HYPERPLASIA
10.3 PRIMARY LIVER CANCER
10.3.1 HEPATOCELLULAR CARCINOMA (HCC)
10.3.2 INTRAHEPATIC CHOLANGIOCARCINOMA (BILE DUCT CANCER)
10.3.3 ANGIOSARCOMA HEMANGIOSARCOMA
10.3.4 HEPATOBLASTOMA
11 MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT
11.1 OVERVIEW
11.2 PLATFORM BASED PRODUCTS
11.2.1 NEXT GENERATION SEQUENCING
11.2.2 MICROARRAYS
11.2.3 PCR
11.2.4 OTHERS
11.3 INSTRUMENT BASED PRODUCTS
11.3.1 IMAGING
11.3.2 BIOPSY
11.4 KITS AND REAGENTS
11.4.1 ELISA TEST KITS
11.4.2 CASSETTE TEST KITS
11.4.3 OTHERS
11.5 OTHER CONSUMABLES
12 MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION
12.1 OVERVIEW
12.2 SCREENING
12.2.1 PLATFORM BASED PRODUCTS
12.2.2 INSTRUMENT BASED PRODUCTS
12.2.3 KITS AND REAGENTS
12.2.4 OTHER CONSUMABLES
12.3 DIAGNOSTIC AND PREDICTIVE
12.3.1 PLATFORM BASED PRODUCTS
12.3.2 INSTRUMENT BASED PRODUCTS
12.3.3 KITS AND REAGENTS
12.3.4 OTHER CONSUMABLES
12.4 PROGNOSTIC
12.4.1 PLATFORM BASED PRODUCTS
12.4.2 INSTRUMENT BASED PRODUCTS
12.4.3 KITS AND REAGENTS
12.4.4 OTHER CONSUMABLES
12.5 RESEARCH
12.5.1 PLATFORM BASED PRODUCTS
12.5.2 INSTRUMENT BASED PRODUCTS
12.5.3 KITS AND REAGENTS
12.5.4 OTHER CONSUMABLES
13 MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY
13.1 OVERVIEW
13.2 FLUORESCENT IN SITU HYBRIDIZATION
13.3 NEXT GENERATION SEQUENCING
13.4 FLUORIMMUNOASSAY
13.5 COMPARATIVE GENOMIC HYBRIDIZATION
13.6 IMMUNOHISTOCHEMICAL
13.7 OTHERS
14 MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET, BY GENDER
14.1 OVERVIEW
14.2 MALE
14.3 FEMALE
15 MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET, BY END USER
15.1 OVERVIEW
15.2 HOSPITALS
15.3 DIAGNOSTIC CENTERS
15.4 CANCER RESEARCH CENTERS
15.5 AMBULATORY SURGICAL CENTERS
15.6 ACADEMIC INSTITUTES
15.7 OTHERS
16 MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL
16.1 OVERVIEW
16.2 DIRECT TENDER
16.3 RETAIL SALES
16.4 OTHERS
17 MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET, BY REGION
17.1 MIDDLE EAST AND AFRICA
17.1.1 SOUTH AFRICA
17.1.2 SAUDI ARABIA
17.1.3 U.A.E.
17.1.4 EGYPT
17.1.5 ISRAEL
17.1.6 REST OF MIDDLE EAST AND AFRICA
18 MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE
18.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA
19 SWOT ANALYSIS
20 COMPANY PROFILE
20.1 F. HOFFMANN-LA ROCHE LTD.
20.1.1 COMPANY SNAPSHOT
20.1.2 REVENUE ANALYSIS
20.1.3 COMPANY SHARE ANALYSIS
20.1.4 PRODUCT PORTFOLIO
20.1.5 RECENT DEVELOPMENT
20.2 KONINLIJKE PHILIPS N.V.
20.2.1 COMPANY SNAPSHOT
20.2.2 REVENUE ANALYSIS
20.2.3 COMPANY SHARE ANALYSIS
20.2.4 PRODUCT PORTFOLIO
20.2.5 RECENT DEVELOPMENT
20.3 THERMO FISHER SCIENTIFIC INC.
20.3.1 COMPANY SNAPSHOT
20.3.2 REVENUE ANALYSIS
20.3.3 COMPANY SHARE ANALYSIS
20.3.4 PRODUCT PORTFOLIO
20.3.5 RECENT DEVELOPMENT
20.4 BD
20.4.1 COMPANY SNAPSHOT
20.4.2 REVENUE ANALYSIS
20.4.3 COMPANY SHARE ANALYSIS
20.4.4 PRODUCT PORTFOLIO
20.4.5 RECENT DEVELOPMENTS
20.5 SIEMENS HEALTHCARE GMBH
20.5.1 COMPANY SNAPSHOT
20.5.2 REVENUE ANALYSIS
20.5.3 COMPANY SHARE ANALYSIS
20.5.4 PRODUCT PORTFOLIO
20.5.5 RECENT DEVELOPMENT
20.6 AGILENT TECHNOLOGIES, INC.
20.6.1 COMPANY SNAPSHOT
20.6.2 REVENUE ANALYSIS
20.6.3 PRODUCT PORTFOLIO
20.6.4 RECENT DEVELOPMENTS
20.7 ABK BIOMEDICAL INC.
20.7.1 COMPANY SNAPSHOT
20.7.2 PRODUCT PORTFOLIO
20.7.3 RECENT DEVELOPMENT
20.8 AB SCIEX PTE LTD. (SUBSIDIARY OF DANAHER.)
20.8.1 COMPANY SNAPSHOT
20.8.2 REVENUE ANALYSIS
20.8.3 PRODUCT PORTFOLIO
20.8.4 RECENT DEVELOPMENT
20.9 ALTOGEN BIOSYSTEMS
20.9.1 COMPANY SNAPSHOT
20.9.2 PRODUCT PORTFOLIO
20.9.3 RECENT DEVELOPMENT
20.1 BIOCEPT, INC.
20.10.1 COMPANY SNAPSHOT
20.10.2 REVENUE ANALYSIS
20.10.3 PRODUCT PORTFOLIO
20.10.4 RECENT DEVELOPMENT
20.11 BODITECH MED INC.
20.11.1 COMPANY SNAPSHOT
20.11.2 PRODUCT PORTFOLIO
20.11.3 RECENT DEVELOPMENTS
20.12 DIAGNOSTIC BIOSYSTEMS INC.
20.12.1 COMPANY SNAPSHOT
20.12.2 PRODUCT PORTFOLIO
20.12.3 RECENT DEVELOPMENT
20.13 DIAZYME LABORATORIES, INC.
20.13.1 COMPANY SNAPSHOT
20.13.2 PRODUCT PORTFOLIO
20.13.3 RECENT DEVELOPMENT
20.14 ELABSCIENCE BIOTECHNOLOGY INC.
20.14.1 COMPANY SNAPSHOT
20.14.2 PRODUCT PORTFOLIO
20.14.3 RECENT DEVELOPMENT
20.15 EPIGENOMICS AG
20.15.1 COMPANY SNAPSHOT
20.15.2 REVENUE ANALYSIS
20.15.3 PRODUCT PORTFOLIO
20.15.4 RECENT DEVELOPMENT
20.16 FUJIFILM CORPORATION
20.16.1 COMPANY SNAPSHOT
20.16.2 REVENUE ANALYSIS
20.16.3 PRODUCT PORTFOLIO
20.16.4 RECENT DEVELOPMENT
20.17 FUJIREBIO
20.17.1 COMPANY SNAPSHOT
20.17.2 PRODUCT PORTFOLIO
20.17.3 RECENT DEVELOPMENTS
20.18 HIPRO BIOTECHNOLOGY CO., LTD.
20.18.1 COMPANY SNAPSHOT
20.18.2 PRODUCT PORTFOLIO
20.18.3 RECENT DEVELOPMENT
20.19 ILLUMINA, INC.
20.19.1 COMPANY SNAPSHOT
20.19.2 REVENUE ANALYSIS
20.19.3 PRODUCT PORTFOLIO
20.19.4 RECENT DEVELOPMENTS
20.2 MOLGEN
20.20.1 COMPANY SNAPSHOT
20.20.2 PRODUCT PORTFOLIO
20.20.3 RECENT DEVELOPMENT
20.21 QIAGEN
20.21.1 COMPANY SNAPSHOT
20.21.2 REVENUE ANALYSIS
20.21.3 PRODUCT PORTFOLIO
20.21.4 RECENT DEVELOPMENT
20.22 Q-LINE BIOTECH PVT LTD.
20.22.1 COMPANY SNAPSHOT
20.22.2 PRODUCT PORTFOLIO
20.22.3 RECENT DEVELOPMENT
20.23 SYSMEX CORPORATION
20.23.1 COMPANY SNAPSHOT
20.23.2 REVENUE ANALYSIS
20.23.3 PRODUCT PORTFOLIO
20.23.4 RECENT DEVELOPMENT
20.24 TEBUBIO
20.24.1 COMPANY SNAPSHOT
20.24.2 PRODUCT PORTFOLIO
20.24.3 RECENT DEVELOPMENT
20.25 TOSOH INDIA PVT. LTD.
20.25.1 COMPANY SNAPSHOT
20.25.2 PRODUCT PORTFOLIO
20.25.3 RECENT DEVELOPMENT
21 QUESTIONNAIRE
22 RELATED REPORTS
List of Table
TABLE 1 DIFFERENT TYPES OF CANCER NON-INVASIVE SCREENING TESTS FOR DIFFERENT TYPES OF CANCERS
TABLE 2 LIVER CANCER RATES
TABLE 3 APPROVED DIAGNOSTICS OF LIVER CANCER
TABLE 4 MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 5 MIDDLE EAST & AFRICA IMAGING IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 6 MIDDLE EAST & AFRICA IMAGING TEST IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 7 MIDDLE EAST & AFRICA MAGNETIC RESONANCE IMAGING (MRI) IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 8 MIDDLE EAST & AFRICA GENETIC TEST IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 9 MIDDLE EAST & AFRICA BIOPSY IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 10 MIDDLE EAST & AFRICA BIOPSY IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 11 MIDDLE EAST & AFRICA OTHERS IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 12 MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 13 MIDDLE EAST & AFRICA STAGE III IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 14 MIDDLE EAST & AFRICA STAGE II IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 15 MIDDLE EAST & AFRICA STAGE IV IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 16 MIDDLE EAST & AFRICA STAGE I IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 17 MIDDLE EAST & AFRICA STAGE 0 IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 18 MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 19 MIDDLE EAST & AFRICA SECONDARY LIVER CANCER IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 20 MIDDLE EAST & AFRICA RENAL CELL CARCINOMA IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 21 MIDDLE EAST & AFRICA CLEAR CELL RENAL CELL CARCINOMA IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 22 MIDDLE EAST & AFRICA CLEAR CELL RENAL CELL CARCINOMA IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 23 MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 24 MIDDLE EAST & AFRICA PLATFORM BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 25 MIDDLE EAST & AFRICA PLATFORM BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 26 MIDDLE EAST & AFRICA INSTRUMENT BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 27 MIDDLE EAST & AFRICA INSTRUMENT BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 28 MIDDLE EAST & AFRICA KITS AND REAGENTS IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 29 MIDDLE EAST & AFRICA KITS AND REAGENTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 30 MIDDLE EAST & AFRICA OTHER CONSUMABLES IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 31 MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 32 MIDDLE EAST & AFRICA SCREENING IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 33 MIDDLE EAST & AFRICA SCREENING IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 34 MIDDLE EAST & AFRICA DIAGNOSTIC AND PREDICTIVE IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 35 MIDDLE EAST & AFRICA DIAGNOSTIC AND PREDICTIVE IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 36 MIDDLE EAST & AFRICA PROGNOSTIC IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 37 MIDDLE EAST & AFRICA PROGNOSTIC IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 38 MIDDLE EAST & AFRICA RESEARCH IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 39 MIDDLE EAST & AFRICA RESEARCH IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 40 MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 41 MIDDLE EAST & AFRICA FLUORESCENT IN SITU HYBRIDIZATION IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 42 MIDDLE EAST & AFRICA NEXT GENERATION SEQUENCING IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 43 MIDDLE EAST & AFRICA FLUORIMMUNOASSAY IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 44 MIDDLE EAST & AFRICA COMPARATIVE GENOMIC HYBRIDIZATION IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 45 MIDDLE EAST & AFRICA IMMUNOHISTOCHEMICAL IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 46 MIDDLE EAST & AFRICA OTHERS IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 47 MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 48 MIDDLE EAST & AFRICA MALE IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 49 MIDDLE EAST & AFRICA FEMALE IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 50 MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 51 MIDDLE EAST & AFRICA HOSPITALS IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 52 MIDDLE EAST & AFRICA DIAGNOSTIC CENTERS IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 53 MIDDLE EAST & AFRICA CANCER RESEARCH CENTERS IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 54 MIDDLE EAST & AFRICA AMBULATORY SURGICAL CENTERS IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 55 MIDDLE EAST & AFRICA ACADEMIC INSTITUTES IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 56 MIDDLE EAST & AFRICA OTHERS IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 57 MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 58 MIDDLE EAST & AFRICA DIRECT TENDER IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 59 MIDDLE EAST & AFRICA RETAIL SALES IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 60 MIDDLE EAST & AFRICA OTHERS IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 61 MIDDLE EAST AND AFRICA LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 62 MIDDLE EAST AND AFRICA IMAGING TEST IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 63 MIDDLE EAST AND AFRICA MAGNETIC RESONANCE IMAGING (MRI) IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE 2021-2030 (USD MILLION)
TABLE 64 MIDDLE EAST AND AFRICA BIOPSY IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 65 MIDDLE EAST AND AFRICA LIVER CANCER DIAGNOSTICS MARKET, BY CANCER STAGES, 2021-2030 (USD MILLION)
TABLE 66 MIDDLE EAST AND AFRICA LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 67 MIDDLE EAST AND AFRICA SECONDARY LIVER CANCER IN LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 68 MIDDLE EAST AND AFRICA PRIMARY LIVER CANCER IN LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 69 MIDDLE EAST AND AFRICA LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 70 MIDDLE EAST AND AFRICA PLATFORM-BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 71 MIDDLE EAST AND AFRICA INSTRUMENT-BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 72 MIDDLE EAST AND AFRICA KITS & REAGENTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 73 MIDDLE EAST AND AFRICA LIVER CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 74 MIDDLE EAST AND AFRICA LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 75 MIDDLE EAST AND AFRICA SCREENING IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 76 MIDDLE EAST AND AFRICA DIAGNOSTIC AND PREDICTIVE IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 77 MIDDLE EAST AND AFRICA PROGNOSTIC IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 78 MIDDLE EAST AND AFRICA RESEARCH IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 79 MIDDLE EAST AND AFRICA LIVER CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 80 MIDDLE EAST AND AFRICA LIVER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 81 MIDDLE EAST AND AFRICA LIVER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 82 SOUTH AFRICA LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 83 SOUTH AFRICA IMAGING TEST IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 84 SOUTH AFRICA MAGNETIC RESONANCE IMAGING (MRI) IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE 2021-2030 (USD MILLION)
TABLE 85 SOUTH AFRICA BIOPSY IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 86 SOUTH AFRICA LIVER CANCER DIAGNOSTICS MARKET, BY CANCER STAGES, 2021-2030 (USD MILLION)
TABLE 87 SOUTH AFRICA LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 88 SOUTH AFRICA SECONDARY LIVER CANCER IN LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 89 SOUTH AFRICA PRIMARY LIVER CANCER IN LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 90 SOUTH AFRICA LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 91 SOUTH AFRICA PLATFORM-BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 92 SOUTH AFRICA INSTRUMENT-BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 93 SOUTH AFRICA KITS & REAGENTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 94 SOUTH AFRICA LIVER CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 95 SOUTH AFRICA LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 96 SOUTH AFRICA SCREENING IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 97 SOUTH AFRICA DIAGNOSTIC AND PREDICTIVE IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 98 SOUTH AFRICA PROGNOSTIC IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 99 SOUTH AFRICA RESEARCH IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 100 SOUTH AFRICA LIVER CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 101 SOUTH AFRICA LIVER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 102 SOUTH AFRICA LIVER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 103 SAUDI ARABIA LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 104 SAUDI ARABIA IMAGING TEST IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 105 SAUDI ARABIA MAGNETIC RESONANCE IMAGING (MRI) IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE 2021-2030 (USD MILLION)
TABLE 106 SAUDI ARABIA BIOPSY IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 107 SAUDI ARABIA LIVER CANCER DIAGNOSTICS MARKET, BY CANCER STAGES, 2021-2030 (USD MILLION)
TABLE 108 SAUDI ARABIA LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 109 SAUDI ARABIA SECONDARY LIVER CANCER IN LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 110 SAUDI ARABIA PRIMARY LIVER CANCER IN LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 111 SAUDI ARABIA LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 112 SAUDI ARABIA PLATFORM-BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 113 SAUDI ARABIA INSTRUMENT-BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 114 SAUDI ARABIA KITS & REAGENTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 115 SAUDI ARABIA LIVER CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 116 SAUDI ARABIA LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 117 SAUDI ARABIA SCREENING IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 118 SAUDI ARABIA DIAGNOSTIC AND PREDICTIVE IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 119 SAUDI ARABIA PROGNOSTIC IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 120 SAUDI ARABIA RESEARCH IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 121 SAUDI ARABIA LIVER CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 122 SAUDI ARABIA LIVER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 123 SAUDI ARABIA LIVER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 124 U.A.E LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 125 U.A.E IMAGING TEST IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 126 U.A.E MAGNETIC RESONANCE IMAGING (MRI) IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE 2021-2030 (USD MILLION)
TABLE 127 U.A.E BIOPSY IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 128 U.A.E LIVER CANCER DIAGNOSTICS MARKET, BY CANCER STAGES, 2021-2030 (USD MILLION)
TABLE 129 U.A.E LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 130 U.A.E SECONDARY LIVER CANCER IN LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 131 U.A.E PRIMARY LIVER CANCER IN LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 132 U.A.E LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 133 U.A.E PLATFORM-BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 134 U.A.E INSTRUMENT-BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 135 U.A.E KITS & REAGENTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 136 U.A.E LIVER CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 137 U.A.E LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 138 U.A.E SCREENING IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 139 U.A.E DIAGNOSTIC AND PREDICTIVE IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 140 U.A.E PROGNOSTIC IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 141 U.A.E RESEARCH IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 142 U.A.E LIVER CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 143 U.A.E LIVER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 144 U.A.E LIVER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 145 EGYPT LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 146 EGYPT IMAGING TEST IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 147 EGYPT MAGNETIC RESONANCE IMAGING (MRI) IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE 2021-2030 (USD MILLION)
TABLE 148 EGYPT BIOPSY IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 149 EGYPT LIVER CANCER DIAGNOSTICS MARKET, BY CANCER STAGES, 2021-2030 (USD MILLION)
TABLE 150 EGYPT LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 151 EGYPT SECONDARY LIVER CANCER IN LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 152 EGYPT PRIMARY LIVER CANCER IN LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 153 EGYPT LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 154 EGYPT PLATFORM-BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 155 EGYPT INSTRUMENT-BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 156 EGYPT KITS & REAGENTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 157 EGYPT LIVER CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 158 EGYPT LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 159 EGYPT SCREENING IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 160 EGYPT DIAGNOSTIC AND PREDICTIVE IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 161 EGYPT PROGNOSTIC IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 162 EGYPT RESEARCH IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 163 EGYPT LIVER CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 164 EGYPT LIVER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 165 EGYPT LIVER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 166 ISRAEL LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 167 ISRAEL IMAGING TEST IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 168 ISRAEL MAGNETIC RESONANCE IMAGING (MRI) IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE 2021-2030 (USD MILLION)
TABLE 169 ISRAEL BIOPSY IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 170 ISRAEL LIVER CANCER DIAGNOSTICS MARKET, BY CANCER STAGES, 2021-2030 (USD MILLION)
TABLE 171 ISRAEL LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 172 ISRAEL SECONDARY LIVER CANCER IN LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 173 ISRAEL PRIMARY LIVER CANCER IN LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 174 ISRAEL LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 175 ISRAEL PLATFORM-BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 176 ISRAEL INSTRUMENT-BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 177 ISRAEL KITS & REAGENTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 178 ISRAEL LIVER CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 179 ISRAEL LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 180 ISRAEL SCREENING IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 181 ISRAEL DIAGNOSTIC AND PREDICTIVE IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 182 ISRAEL PROGNOSTIC IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 183 ISRAEL RESEARCH IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 184 ISRAEL LIVER CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 185 ISRAEL LIVER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 186 ISRAEL LIVER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 187 REST OF MIDDLE EAST AND AFRICA LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
List of Figure
FIGURE 1 MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET: DATA TRIANGULATION
FIGURE 3 MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET: MIDDLE EAST & AFRICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 8 MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET: DBMR MARKET POSITION GRID
FIGURE 9 MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET: SEGMENTATION
FIGURE 11 GROWING AWARENESS OF LIVER CANCER AND INCREASING HEALTHCARE EXPENDITURE ARE EXPECTED TO DRIVE THE GROWTH OF THE MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET FROM 2023 TO 2030
FIGURE 12 THE IMAGING TEST SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET IN 2023 & 2030
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET
FIGURE 14 THE MIDDLE EAST & AFRICA MORTALITY RATE DUE TO CANCER
FIGURE 15 INCREASING MIDDLE EAST & AFRICA CANCER RATE IN 2020
FIGURE 16 BARRIERS TO EARLY CANCER DIAGNOSIS AND TREATMENT
FIGURE 17 MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET: BY TEST TYPE, 2022
FIGURE 18 MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET: BY TEST TYPE, 2023-2030 (USD MILLION)
FIGURE 19 MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET: BY TEST TYPE, CAGR (2023-2030)
FIGURE 20 MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET: BY TEST TYPE, LIFELINE CURVE
FIGURE 21 MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET: BY CANCER STAGE, 2022
FIGURE 22 MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET: BY CANCER STAGE, 2023-2030 (USD MILLION)
FIGURE 23 MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET: BY CANCER STAGE, CAGR (2023-2030)
FIGURE 24 MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET: BY CANCER STAGE, LIFELINE CURVE
FIGURE 25 MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, 2022
FIGURE 26 MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, 2023-2030 (USD MILLION)
FIGURE 27 MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, CAGR (2023-2030)
FIGURE 28 MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, LIFELINE CURVE
FIGURE 29 MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET: BY PRODUCT, 2022
FIGURE 30 MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET: BY PRODUCT, 2023-2030 (USD MILLION)
FIGURE 31 MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET: BY PRODUCT, CAGR (2023-2030)
FIGURE 32 MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET: BY PRODUCT, LIFELINE CURVE
FIGURE 33 MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET: BY APPLICATION, 2022
FIGURE 34 MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET: BY APPLICATION, 2023-2030 (USD MILLION)
FIGURE 35 MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET: BY APPLICATION, CAGR (2023-2030)
FIGURE 36 MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 37 MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET: BY TECHNOLOGY, 2022
FIGURE 38 MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET: BY TECHNOLOGY, 2023-2030 (USD MILLION)
FIGURE 39 MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET: BY TECHNOLOGY, CAGR (2023-2030)
FIGURE 40 MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET: BY TECHNOLOGY, LIFELINE CURVE
FIGURE 41 MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET: BY GENDER, 2022
FIGURE 42 MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET: BY GENDER, 2023-2030 (USD MILLION)
FIGURE 43 MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET: BY GENDER, CAGR (2023-2030)
FIGURE 44 MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET: BY GENDER, LIFELINE CURVE
FIGURE 45 MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET: BY END USER, 2022
FIGURE 46 MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET: BY END USER, 2023-2030 (USD MILLION)
FIGURE 47 MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET: BY END USER, CAGR (2023-2030)
FIGURE 48 MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET: BY END USER, LIFELINE CURVE
FIGURE 49 MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2022
FIGURE 50 MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)
FIGURE 51 MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 52 MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 53 MIDDLE EAST AND AFRICA LIVER CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022)
FIGURE 54 MIDDLE EAST AND AFRICA LIVER CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022)
FIGURE 55 MIDDLE EAST AND AFRICA LIVER CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030)
FIGURE 56 MIDDLE EAST AND AFRICA LIVER CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030)
FIGURE 57 MIDDLE EAST AND AFRICA LIVER CANCER DIAGNOSTICS MARKET: TEST TYPE (2023-2030)
FIGURE 58 MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%)
منهجية البحث
يتم جمع البيانات وتحليل سنة الأساس باستخدام وحدات جمع البيانات ذات أحجام العينات الكبيرة. تتضمن المرحلة الحصول على معلومات السوق أو البيانات ذات الصلة من خلال مصادر واستراتيجيات مختلفة. تتضمن فحص وتخطيط جميع البيانات المكتسبة من الماضي مسبقًا. كما تتضمن فحص التناقضات في المعلومات التي شوهدت عبر مصادر المعلومات المختلفة. يتم تحليل بيانات السوق وتقديرها باستخدام نماذج إحصائية ومتماسكة للسوق. كما أن تحليل حصة السوق وتحليل الاتجاهات الرئيسية هي عوامل النجاح الرئيسية في تقرير السوق. لمعرفة المزيد، يرجى طلب مكالمة محلل أو إرسال استفسارك.
منهجية البحث الرئيسية التي يستخدمها فريق بحث DBMR هي التثليث البيانات والتي تتضمن استخراج البيانات وتحليل تأثير متغيرات البيانات على السوق والتحقق الأولي (من قبل خبراء الصناعة). تتضمن نماذج البيانات شبكة تحديد موقف البائعين، وتحليل خط زمني للسوق، ونظرة عامة على السوق ودليل، وشبكة تحديد موقف الشركة، وتحليل براءات الاختراع، وتحليل التسعير، وتحليل حصة الشركة في السوق، ومعايير القياس، وتحليل حصة البائعين على المستوى العالمي مقابل الإقليمي. لمعرفة المزيد عن منهجية البحث، أرسل استفسارًا للتحدث إلى خبراء الصناعة لدينا.
التخصيص متاح
تعد Data Bridge Market Research رائدة في مجال البحوث التكوينية المتقدمة. ونحن نفخر بخدمة عملائنا الحاليين والجدد بالبيانات والتحليلات التي تتطابق مع هدفهم. ويمكن تخصيص التقرير ليشمل تحليل اتجاه الأسعار للعلامات التجارية المستهدفة وفهم السوق في بلدان إضافية (اطلب قائمة البلدان)، وبيانات نتائج التجارب السريرية، ومراجعة الأدبيات، وتحليل السوق المجدد وقاعدة المنتج. ويمكن تحليل تحليل السوق للمنافسين المستهدفين من التحليل القائم على التكنولوجيا إلى استراتيجيات محفظة السوق. ويمكننا إضافة عدد كبير من المنافسين الذين تحتاج إلى بيانات عنهم بالتنسيق وأسلوب البيانات الذي تبحث عنه. ويمكن لفريق المحللين لدينا أيضًا تزويدك بالبيانات في ملفات Excel الخام أو جداول البيانات المحورية (كتاب الحقائق) أو مساعدتك في إنشاء عروض تقديمية من مجموعات البيانات المتوفرة في التقرير.
